Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company developing allogeneic gamma delta CAR T cell therapies for autoimmune diseases and cancer. The ACET news feed on Stock Titan aggregates company-issued updates, SEC-linked announcements, and other coverage related to Adicet’s clinical programs, capital markets activity, and regulatory interactions.
Investors and followers of Adicet Bio can use this page to review news on its lead program, prulacabtagene leucel (prula-cel, formerly ADI-001), an investigational allogeneic gamma delta CAR T therapy targeting B cells via an anti-CD20 CAR. Company releases have highlighted Phase 1 data in lupus nephritis and systemic lupus erythematosus, enrollment across additional autoimmune indications such as systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA associated vasculitis and treatment-refractory rheumatoid arthritis, and regulatory designations including Fast Track status for several of these conditions.
The ACET news stream also reflects Adicet’s oncology work, including updates on ADI-212, a next-generation, gene-edited and armored gamma delta CAR T candidate targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer. Preclinical data presentations, plans for regulatory filings, and development timelines are typically communicated through press releases and associated 8-K filings.
Beyond clinical and scientific developments, Adicet Bio’s news includes information on registered direct offerings of common stock and pre-funded warrants, reverse stock split decisions, Nasdaq listing status notices, workforce and pipeline prioritization actions, and participation in healthcare conferences. By reviewing this curated ACET news page, readers can follow how Adicet reports progress in its autoimmune and oncology pipelines, how it manages its capital structure, and how key milestones are communicated through official channels.
Adicet Bio (Nasdaq: ACET) has reported its Q1 2024 financial results and key business updates. The company is set to initiate a Phase 1 clinical trial for ADI-001 in lupus nephritis in Q2 2024, following FDA clearance. Preliminary data is expected by late 2024 or early 2025. Adicet also presented promising preclinical data on ADI-270 at the ASGCT annual meeting, with plans to file an IND for ADI-270 in renal cell carcinoma in Q2 2024. Financially, the company has a robust balance sheet with $247.6 million in cash and equivalents, projecting fund sufficiency until the second half of 2026. R&D expenses decreased to $23.9 million from $26.8 million YoY, while G&A expenses increased slightly to $7.0 million from $6.6 million YoY. Net loss for Q1 2024 was $28.0 million, or $0.35 per share, an improvement from $30.9 million, or $0.72 per share, in Q1 2023.
Adicet Bio (Nasdaq: ACET), a clinical-stage biotech firm specializing in gamma delta T cell therapies for autoimmune diseases and cancer, will present preclinical data on ADI-270 at the 2024 European Hematology Association (EHA) Hybrid Congress. The event, held in Madrid, Spain from June 13-16, 2024, will feature Yvan Chanthery, Ph.D., presenting on June 14 at 18:00 CEST. ADI-270 is an armored allogeneic anti-CD70 CAR γδ T cell therapy aimed at multiple solid and hematological cancers.
Adicet Bio, Inc. (Nasdaq: ACET) will participate in a fireside chat at the 2024 Citizens JMP Life Sciences Conference in New York. Chen Schor, President and CEO, will present on May 14, 2024, at 1:30 p.m. ET. The presentation can be accessed on the Investors section of Adicet Bio's website.
Adicet Bio, Inc. (Nasdaq: ACET) granted an inducement award on April 30, 2024, to a new employee. The award consists of non-qualified stock options to purchase 7,800 shares at $1.49 per share. Vesting occurs over four years, with one-fourth vesting after one year and the rest in monthly installments. The award was granted outside Adicet's equity plans under the Inducement Plan.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.